Navigation Links
Anti-tumor drugs tested by microfluidic device
Date:10/5/2010

Washington, D.C. (October 5, 2010) -- A prototype device developed in Hong Kong will allow laboratory researchers to non-invasively test drugs for their ability to kill tumors by subjecting cancerous cells with different concentration gradients. The new device is built upon microfluidics -- a set of technologies that allows the control and manipulation of fluids at the sub-millimeter scale -- and is described in the American Institute of Physics' journal Biomicrofluidics.

Microfluidic valves within the device, said Hongkai Wu of Hong Kong University of Science and Technology, accurately meter different solutions and mix them to form a stepwise succession of gradients. Then assays measuring cell apoptosis are applied. The device integrates a previously validated analysis method that quantifies the apoptotic process at the level of single cells in real-time.

For this test, researchers measured the activity of the drug etoposide in HeLa cells. Etoposide is a commercially available anticancer compound commonly used in chemotherapy. HeLa cells, derived from human cervical cancer cells, are a line of cells frequently used in research.

The device allows researchers to study the cytotoxicity of multiple concentrations of a drug in parallel on one chip, saving both time and labor and reducing errors caused by variations in conditions often found in larger-scale testing. Also, microfluidic chambers within the device allow long-term tracking of individual cells through fluorescent microscopic imaging that offers high optical sensitivity.

With some other in vitro tests, like DNA analysis, cells need to be killed in order to be studied. In this analysis method, a change in fluorescence occurs when caspase-3, an indicator of cell apoptosis, is activated. In Wu's test, increasing concentrations of etoposide demonstrated correspondingly higher activation of caspase-3. In a control-group chip without etoposide, caspase-3 was not activated.

Wu also said that, "Unlike conventional methods, the microfluidic device permits quantitative data to be obtained from individual cells; the device requires fewer numbers of cells and allows testing of amounts of reagents reduced by about 4 orders of magnitude. In a conventional 96-well plate study, each well is around 1 centimeter, while in our microchip device, each cell chamber has a dimension of hundreds of microns. Reducing the sample size has significant merit because in most cases, the biomolecules in use are extremely expensive, even in quantities in milligrams or less."

While this report concerns a test of five ladder channels on a single chip, higher throughputs should be possible, Wu stated. "This prototype system should be useful in the areas of biology and bioengineering, especially for discovering apoptosis-inducing agents," Wu concluded.


'/>"/>

Contact: Jason Bardi
jbardi@aip.org
301-209-3091
American Institute of Physics
Source:Eurekalert

Related biology news :

1. Researchers identify new anti-tumor gene
2. Childrens National researchers develop novel anti-tumor vaccine
3. Iowa State, Ames Lab researchers identify structure that allows bacteria to resist drugs
4. White House policy advisor talks about legalized drugs
5. Ingredient in soap points toward new drugs for infection that affects 2 billion
6. Case Western Reserve researcher discovers new anti-pathogenic drugs to treat MRSA
7. Scripps scientists develop test providing new pathway for identifying obesity, diabetes drugs
8. U of M researchers identify 2 FDA approved drugs that may fight HIV
9. Scientists reveal new targets for anti-angiogenesis drugs
10. Drugs encased in nanoparticles travel to tumors on the surface of immune-system cells
11. Molecules delivering drugs as they walk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/5/2017)... KEY FINDINGS The global market for stem ... 25.76% during the forecast period of 2017-2025. The rise ... growth of the stem cell market. Download ... The global stem cell market is segmented on the ... cell market of the product is segmented into adult ...
(Date:4/3/2017)... WASHINGTON , April 3, 2017 /PRNewswire-USNewswire/ ... single-cell precision engineering platform, detected a statistically ... cell product prior to treatment and objective ... highlight the potential to predict whether cancer ... prior to treatment, as well as to ...
(Date:3/30/2017)... 30, 2017 The research team of The ... (3D) fingerprint identification by adopting ground breaking 3D fingerprint minutiae recovery ... of speed and accuracy for use in identification, crime investigation, immigration ... ... A research team ...
Breaking Biology News(10 mins):
(Date:6/22/2017)... ... June 22, 2017 , ... ... RegMedNet has produced a Spotlight series on “Cell Therapy Regulation” ... perspectives by leading experts on the unique regulatory challenges of stem cell medical ...
(Date:6/22/2017)... ... ... Charm Sciences, Inc. is pleased to announce that its Charm Amphenicol (AMPH) test ... screening test at dairies and farms for raw commingled cow milk. The test was ... system. These systems are a combination incubator and reader in one. , “The AMPH ...
(Date:6/20/2017)... , June 20, 2017  Kibow Biotech Inc., a ... announce the issuance of a new patent covering a ... by the U.S. Patent and Trademark Office on May ... of the Buzz of Bio award in 2014 in ... to developing non-drug approaches to chronic disease. Renadyl™, the ...
(Date:6/19/2017)... (PRWEB) , ... June 19, 2017 , ... ... overseeing all service activities supporting EDETEK’s products including training, implementation, support, and client ... to his new role. He has previously held leadership roles for service providers ...
Breaking Biology Technology: